Live Breaking News & Updates on Protagonist Therapeutics Daily|Page 7

Stay updated with breaking news from Protagonist therapeutics daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

50,000 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Purchased by Ghisallo Capital Management LLC

Ghisallo Capital Management LLC acquired a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 50,000 shares of the company’s stock, valued at approximately $1,381,000. Ghisallo Capital Management LLC owned approximately 0.09% of Protagonist Therapeutics as […] ....

United States , Group Plc , Principal Financial Group Inc , York Mellon Corp , Protagonist Therapeutics Inc , Ameritas Investment Partners Inc , Ghisallo Capital Management , Jpmorgan Chase Co , Protagonist Therapeutics , Free Report , Capital Management , Retirement System , Investment Partners , General Group Plc , New York Mellon Corp , Principal Financial Group , Financial Group , Get Free Report , One Financial , Protagonist Therapeutics Daily , Nasdaq Ptgx , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Protagonist Therapeutics (NASDAQ:PTGX) Earns Overweight Rating from Analysts at Capital One Financial

Capital One Financial assumed coverage on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research note released on Monday, MarketBeat.com reports. The brokerage issued an overweight rating and a $32.00 price target on the stock. Capital One Financial also issued estimates for Protagonist Therapeutics’ Q3 2023 earnings at ($0.68) EPS, Q4 2023 earnings […] ....

Blackrock Inc , Protagonist Therapeutics Inc , Jpmorgan Chase Co , Vanguard Group Inc , Protagonist Therapeutics Company Profile , Capital One Financial , Protagonist Therapeutics , Free Report , One Financial , Moderate Buy , Get Free Report , Street Corp , Vanguard Group , Protagonist Therapeutics Daily , Nasdaq Ptgx , Initiated Coverage , Capital One Financial Co ,

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Gratus Capital LLC

Gratus Capital LLC lifted its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 3.7% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 219,586 shares of the company’s stock after purchasing an additional 7,855 shares during the quarter. Gratus […] ....

Vanguard Group Inc , Blackrock Inc , Securities Exchange Commission , Jpmorgan Chase Co , Protagonist Therapeutics Inc , Gratus Capital , Protagonist Therapeutics , Free Report , Street Corp , Vanguard Group , Get Free Report , Visit Holdingschannel , Protagonist Therapeutics Daily , Nasdaq Ptgx , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Protagonist Therapeutics (NASDAQ:PTGX) Cut to Sell at StockNews.com

StockNews.com lowered shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) from a hold rating to a sell rating in a research report released on Wednesday. PTGX has been the topic of several other reports. JMP Securities lifted their target price on Protagonist Therapeutics from $28.00 to $35.00 in a report on Thursday, July 6th. HC […] ....

Jpmorgan Chase Co , Protagonist Therapeutics Inc , Vanguard Group Inc , Protagonist Therapeutics Company Profile , Blackrock Inc , Protagonist Therapeutics , Free Report , Get Free Report , Street Corp , Vanguard Group , Protagonist Therapeutics Daily , Nasdaq Ptgx , Stocknews Com ,

Protagonist Therapeutics (NASDAQ:PTGX) Earns "Buy" Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a report released on Tuesday morning, Benzinga reports. They currently have a $38.00 price objective on the stock. A number of other research analysts also recently issued reports on the stock. StockNews.com downgraded shares of Protagonist Therapeutics from a […] ....

Hong Kong , Jpmorgan Chase Co , Proshare Advisors , Protagonist Therapeutics Company Profile , Ameritas Investment Partners Inc , Tower Research Capital , Hong Kong Ltd , Protagonist Therapeutics Inc , Royal Bank , Protagonist Therapeutics , Free Report , Get Free Report , Research Capital , Investment Partners , Kong Ltd , Protagonist Therapeutics Daily , Nasdaq Ptgx , Reiterated Rating , Hc Wainwright ,